EOM Pharmaceutical Holdings Inc. (IMUC)

[Investor100]

ImmunoCellular Therapeutics Reports Progress in Two Lead Cancer Immunotherapy Programs
Over 100 Patients Screened in Phase 3 ICT-107 Trial in Newly Diagnosed Glioblastoma;
CIRM Award Payment of $1.5 Million Received;
ICT-121 Phase 1 Trial in Recurrent Glioblastoma Fully Enrolled

http://investors.imuc.com/releasedetail.cfm?ReleaseID=980859

http://clinicaltrials.pharmaceutical-business-review.com/news/immunocellular-secures-grant-for-clinical-trial-of-glioblastoma-250915-4678611

LOS ANGELES, July 25, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today reported progress in its two lead cancer immunotherapy clinical programs: the phase 3 registrational trial of ICT-107 for newly diagnosed glioblastoma and the phase 1 trial of ICT-121 for recurrent glioblastoma.

As previously disclosed, in September of 2015, The California Institute of Regenerative Medicine (CIRM) awarded ImmunoCellular up to $19.9 million toward financing the ICT-107 phase 3 trial. This award is distributed to ImmunoCellular in milestone payments that are primarily dependent on patient enrollment and randomization. In June 2016, ImmunoCellular amended the terms of its award from CIRM to (i) increase the project initial payment by $1.5 million, and (ii) reduce the potential future milestone payments by a corresponding $1.5 million. The potential total amount of the award from CIRM remains at $19.9 million, inclusive of amounts received to date. On July 18, 2016, ImmunoCellular received the $1.5 million payment from CIRM related to the increase in the project initial payment. To date, ImmunoCellular has received $5.5 million from CIRM.

Investor 100